THC BioMed Intl Ltd. has retained the services of Toronto-based Oak Hill Financial to assist with investor relations activities. THC has partnered with Oak Hill to enhance its visibility and profile to the public and in the financial community.
Oak Hill has been engaged for a three-month period. Oak Hill is to provide THC with Canadian investor relations advisory activities. The total cost to THC over the term of the agreement is $24,000 plus HST and THC will also issue 300,000 options to Oak Hill with an price equal to the higher of the closing price of the Company’s common shares on the day before or the day of issuance.
Oak Hill and THC are not related parties and operate at arm’s length. Aside from the options issued by THC to Oak Hill, Oak Hill does not have any additional interest in THC’s securities, directly or indirectly, or any right or intent to acquire such an interest.
“Oak Hill is going to ensure that the story of our company gets out to investors and the Canadian investment community while we expand our product lines and looking at further opportunities,” said John Miller, CEO of THC. ”
THC BioMed is one of Canada’s oldest active licensed cannabis companies. It was first licensed to deal with cannabis in 2013 under a Health Canada Section 56 exemption under the Controlled Drugs and Substances Act and has been a Licensed Producer under the current regime since 2016. It is a small batch producer and aims to be a leader in the beverage and edible space. Please visit our website for a more detailed description of our business and services available. www.thcbiomed.com